Cerebrospinal fluid corticotropin-releasing hormone in healthy humans: effects of yohimbine and naloxone. 2000

M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519, USA. Vythim@nih.gov

CRH neurons projecting from the paraventricular nucleus (PVN) of the hypothalamus to the median eminence control hypothalamic-pituitary-adrenal (HPA) axis activity. However, CRH neurons outside the PVN as well as PVN neurons projecting to sites other than the median eminence also contribute to the stress response and may play a role in mood and anxiety disorders. We have attempted to investigate possible noradrenergic and opioid regulation of these non-HPA CRH neurons. We hypothesized that yohimbine (an alpha2-adrenergic antagonist) would have stimulatory action on non-HPA CRH neurons, whereas naloxone (a mu-opioid receptor antagonist) would not have this effect. Adult normal volunteers received i.v. yohimbine (n = 5; 0.4 microg/kg), naloxone (n = 4; 125 microg/kg), or placebo (n = 3; 0.9% saline). Cerebrospinal fluid (CSF) was collected continuously, and concentrations of CSF CRH, CSF norepinephrine (NE), and plasma cortisol were measured. Administration of either yohimbine or naloxone caused significant increases in plasma cortisol concentrations over time. Although yohimbine robustly increased CSF NE levels and appeared to increase CSF CRH levels, these effects were not seen after naloxone or placebo administration. Intraindividual correlations were not observed between the measured concentrations of plasma cortisol and CSF CRH for any of the subjects. The results support the idea that CSF CRH concentrations reflect the activity of non-HPA CRH neurons. Although both yohimbine and naloxone stimulated the HPA axis, only yohimbine appeared to have stimulatory effects on central NE and non-HPA CRH.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009270 Naloxone A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. MRZ 2593-Br,MRZ-2593,Nalone,Naloxon Curamed,Naloxon-Ratiopharm,Naloxone Abello,Naloxone Hydrobromide,Naloxone Hydrochloride,Naloxone Hydrochloride Dihydride,Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer,Narcan,Narcanti,Abello, Naloxone,Curamed, Naloxon,Dihydride, Naloxone Hydrochloride,Hydrobromide, Naloxone,Hydrochloride Dihydride, Naloxone,Hydrochloride, Naloxone,MRZ 2593,MRZ 2593 Br,MRZ 2593Br,MRZ2593,Naloxon Ratiopharm
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
June 1992, The Journal of clinical endocrinology and metabolism,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
December 2004, BMC neuroscience,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
June 2001, Brain research,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
July 1994, The Journal of clinical endocrinology and metabolism,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
July 1990, Acta psychiatrica Scandinavica,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
March 1996, Annals of the New York Academy of Sciences,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
September 1989, Acta psychiatrica Scandinavica,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
January 1991, Life sciences,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
August 1997, Biological psychiatry,
M Vythilingam, and G M Anderson, and M J Owens, and T M Halaszynski, and J D Bremner, and L L Carpenter, and G R Heninger, and C B Nemeroff, and D S Charney
May 1992, Endocrine reviews,
Copied contents to your clipboard!